PFE“>
When high yield signals high risk
A 7% yield is a red flag in a market full of green. Pfizer trades at 8.1 times forward earnings-a number that screams “caution.” Earnings are projected to decline 3% annually through 2029. Peers like Johnson & Johnson (2.9%) and Merck (3.9%) offer lower yields but stronger balance sheets. AbbVie’s 3.1% isn’t bad either. These companies trade stability for greed. Pfizer’s dividend is a gamble that management can outwit patent cliffs and pipeline failures. It’s a bet with no guaranteed payout.
The dividend is safe through 2026, perhaps with token raises. But long-term? The board will face choices. A cut isn’t imminent, but growth is a fantasy. Buying Pfizer for its dividend is betting against entropy itself. The 7% yield is a warning label, not a promise. So it goes.
The payout will survive the next few years, maybe with small increases. But the long-term outlook is a question mark. Pfizer’s 7% dividend is less a gift than a dare. Investors are invited to dance with the devil-on a sinking ship. 🚩
Read More
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Wuchang Fallen Feathers Save File Location on PC
- Gold Rate Forecast
- Brown Dust 2 Mirror Wars (PvP) Tier List – July 2025
- Crypto Chaos: Is Your Portfolio Doomed? 😱
- HSR 3.7 breaks Hidden Passages, so here’s a workaround
- 17 Black Actresses Who Forced Studios to Rewrite “Sassy Best Friend” Lines
- The 10 Most Beautiful Women in the World for 2026, According to the Golden Ratio
- The Best Single-Player Games Released in 2025
- Where to Change Hair Color in Where Winds Meet
2025-09-01 13:20